Previous close | 16.92 |
Open | 17.77 |
Bid | 17.40 x 0 |
Ask | 19.70 x 0 |
Day's range | 17.55 - 20.51 |
52-week range | 10.98 - 29.90 |
Volume | |
Avg. volume | 251,095 |
Market cap | 27.692M |
Beta (5Y monthly) | 1.04 |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.70 |
Earnings date | 23 Jan 2023 - 27 Jan 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 175.00 |
OXFORD, England, February 06, 2023--Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces the publication of compelling results involving OBD’s technology in the multi-disciplinary PROSTAGRAM study using blood to detect prostate cancer in an at risk population. These results were referred to in the recent results statement.
Whilst it may not be a huge deal, we thought it was good to see that the Oxford BioDynamics Plc ( LON:OBD...
Oxford BioDynamics ( LON:OBD ) Full Year 2022 Results Key Financial Results Net loss: UK£6.71m (flat on FY 2021...